Andrew Hill

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3249672/publications.pdf

Version: 2024-02-01

62 papers	1,835 citations	394286 19 h-index	265120 42 g-index
63 all docs	63 docs citations	63 times ranked	2803 citing authors

#	Article	IF	Citations
1	Harnessing Yarrowia lipolytica lipogenesis to create a platform for lipid and biofuel production. Nature Communications, 2014, 5, 3131.	5.8	488
2	Porphyrinâ€“phospholipid liposomes permeabilized by near-infrared light. Nature Communications, 2014, 5, 3546.	5.8	282
3	Overcoming Gene-Delivery Hurdles: Physiological Considerations for Nonviral Vectors. Trends in Biotechnology, 2016, 34, 91-105.	4.9	132
4	Metabolic engineering of Yarrowia lipolytica for itaconic acid production. Metabolic Engineering, 2015, 32, 66-73.	3.6	119
5	Phenotypic Variation during Biofilm Formation: Implications for Anti-Biofilm Therapeutic Design. Materials, 2018, 11, 1086.	1.3	49
6	Mannosylated poly(beta-amino esters) for targeted antigen presenting cell immune modulation. Biomaterials, 2015, 37, 333-344.	5.7	43
7	Directed vaccination against pneumococcal disease. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 6898-6903.	3.3	39
8	Heterologous production of plant-derived isoprenoid products in microbes and the application of metabolic engineering and synthetic biology. Current Opinion in Plant Biology, 2014, 19, 8-13.	3.5	38
9	Reconstitution of Kinamycin Biosynthesis within the Heterologous Host Streptomyces albus J1074. Journal of Natural Products, 2018, 81, 72-77.	1.5	35
10	E. coli metabolic engineering for gram scale production of a plant-based anti-inflammatory agent. Metabolic Engineering, 2016, 38, 382-388.	3.6	34
11	Tailoring pathway modularity in the biosynthesis of erythromycin analogs heterologously engineered in E. coli. Science Advances, 2015, 1, e1500077.	4.7	32
12	Heterologous Biosynthesis of Type II Polyketide Products Using E. coli. ACS Chemical Biology, 2020, 15, 1177-1183.	1.6	31
13	Total Biosynthesis and Diverse Applications of the Nonribosomal Peptide-Polyketide Siderophore Yersiniabactin. Applied and Environmental Microbiology, 2015, 81, 5290-5298.	1.4	28
14	Comprehensive vaccine design for commensal disease progression. Science Advances, 2017, 3, e1701797.	4.7	28
15	Production of the polyketide 6-deoxyerythronolide B in the heterologous host Bacillus subtilis. Applied Microbiology and Biotechnology, 2016, 100, 1209-1220.	1.7	27
16	Heterologous erythromycin production across strain and plasmid construction. Biotechnology Progress, 2018, 34, 271-276.	1.3	26
17	Structureâ€“Function Assessment of Mannosylated Poly(Î²-amino esters) upon Targeted Antigen Presenting Cell Gene Delivery. Biomacromolecules, 2015, 16, 1534-1541.	2.6	24
18	Grafting Activated Graphene Oxide Nanosheets onto Ultrafiltration Membranes Using Polydopamine to Enhance Antifouling Properties. ACS Applied Materials & Interfaces, 2020, 12, 48179-48187.	4.0	24

#	Article	IF	Citations
19	Recent progress in therapeutic natural product biosynthesis using Escherichia coli. Current Opinion in Biotechnology, 2016, 42, 7-12.	3.3	23
20	Siderophore natural products as pharmaceutical agents. Current Opinion in Biotechnology, 2021, 69, 242-251.	3.3	23
21	Heterologous biosynthesis as a platform for producing new generation natural products. Current Opinion in Biotechnology, 2020, 66, 123-130.	3.3	19
22	In situ pneumococcal vaccine production and delivery through a hybrid biological-biomaterial vector. Science Advances, 2016, 2, e1600264.	4.7	18
23	Engineering a Next-Generation Glycoconjugate-LikeStreptococcus pneumoniaeVaccine. ACS Infectious Diseases, 2018, 4, 1553-1563.	1.8	18
24	Monacycliones Gâ€“K and ent-Gephyromycin A, Angucycline Derivatives from the Marine-Derived Streptomyces sp. HDN15129. Journal of Natural Products, 2020, 83, 2749-2755.	1.5	18
25	Improved heterologous production of the nonribosomal peptideâ€polyketide siderophore yersiniabactin through metabolic engineering and induction optimization. Biotechnology Progress, 2016, 32, 1412-1417.	1.3	17
26	Loading and releasing ciprofloxacin in photoactivatable liposomes. Biochemical Engineering Journal, 2019, 141, 43-48.	1.8	17
27	The Continuing Development of E. coli as a Heterologous Host for Complex Natural Product Biosynthesis. Methods in Molecular Biology, 2016, 1401, 121-134.	0.4	13
28	Influence of molecular weight upon mannosylated bio-synthetic hybrids for targeted antigen presenting cell gene delivery. Biomaterials, 2015, 58, 103-111.	5.7	11
29	Flux Balance Analysis for Media Optimization and Genetic Targets to Improve Heterologous Siderophore Production. IScience, 2020, 23, 101016.	1.9	11
30	Vaccine Delivery and Immune Response Basics. Methods in Molecular Biology, 2021, 2183, 1-8.	0.4	11
31	Contemporary approaches for nonviral gene therapy. Discovery Medicine, 2015, 19, 447-54.	0.5	11
32	Improved Escherichia coli Bactofection and Cytotoxicity by Heterologous Expression of Bacteriophage Î¦X174 Lysis Gene E. Molecular Pharmaceutics, 2015, 12, 1691-1700.	2.3	10
33	Yersiniabactin metal binding characterization and removal of nickel from industrial wastewater. Biotechnology Progress, 2017, 33, 1548-1554.	1.3	10
34	Antibacterial p-Terphenyl with a Rare 2,2â€²-Bithiazole Substructure and Related Compounds Isolated from the Marine-Derived Actinomycete Nocardiopsis sp. HDN154086. Journal of Natural Products, 2021, 84, 1226-1231.	1.5	10
35	Complex natural product production methods and options. Synthetic and Systems Biotechnology, 2021, 6, 1-11.	1.8	10
36	Biomaterials at the interface of nano- and micro-scale vectorâ€“cellular interactions in genetic vaccine design. Journal of Materials Chemistry B, 2014, 2, 8053-8068.	2.9	8

#	Article	IF	Citations
37	Molecular variation of the nonribosomal peptideâ€polyketide siderophore yersiniabactin through biosynthetic and metabolic engineering. Biotechnology and Bioengineering, 2016, 113, 1067-1074.	1.7	8
38	Enhancing vaccine effectiveness with delivery technology. Current Opinion in Biotechnology, 2016, 42, 24-29.	3.3	8
39	Broadened glycosylation patterning of heterologously produced erythromycin. Biotechnology and Bioengineering, 2018, 115, 2771-2777.	1.7	8
40	PEGylated Amine-Functionalized Poly(Îµ-caprolactone) for the Delivery of Plasmid DNA. Materials, 2020, 13, 898.	1.3	8
41	Bimodal Targeting Using Sulfonated, Mannosylated <scp>PEI</scp> for Combined Gene Delivery and Photodynamic Therapy. Photochemistry and Photobiology, 2017, 93, 600-608.	1.3	7
42	Engineering Heterologous Production of Salicylate Glucoside and Glycosylated Variants. Frontiers in Microbiology, 2018, 9, 2241.	1.5	7
43	Influenza Virus Infects and Depletes Activated Adaptive Immune Responders. Advanced Science, 2021, 8, e2100693.	5.6	7
44	Increased production of yersiniabactin and an anthranilate analog through media optimization. Biotechnology Progress, 2017, 33, 1193-1200.	1.3	6
45	Intranasal Vaccine Delivery Technology for Respiratory Tract Disease Application with a Special Emphasis on Pneumococcal Disease. Vaccines, 2021, 9, 589.	2.1	6
46	Liposomal Encapsulation of Polysaccharides (LEPS) as an Effective Vaccine Strategy to Protect Aged Hosts Against S. pneumoniae Infection. Frontiers in Aging, 2021, 2, .	1.2	6
47	Liposomal Dual Delivery of Both Polysaccharide and Protein Antigens. Methods in Molecular Biology, 2021, 2183, 477-487.	0.4	4
48	Pressing diseases that represent promising targets for gene therapy. Discovery Medicine, 2017, 24, 313-322.	0.5	4
49	Design Variation of a Dual-Antigen Liposomal Vaccine Carrier System. Materials, 2019, 12, 2809.	1.3	3
50	Consolidated plasmid Design for Stabilized Heterologous Production of the complex natural product Siderophore Yersiniabactin. Biotechnology Progress, 2021, 37, e3103.	1.3	3
51	Antigen delivery format variation and formulation stability through use of a hybrid vector. Vaccine: X, 2019, 1, 100012.	0.9	2
52	Extended Polysaccharide Analysis within the Liposomal Encapsulation of Polysaccharides System. Materials, 2020, 13, 3320.	1.3	2
53	Yarrowia lipolytica as a Cell Factory for Oleochemical Biotechnology. , 2016, , 1-18.		2
54	Yarrowia lipolytica as a Cell Factory for Oleochemical Biotechnology. , 2017, , 459-476.		1

#	Article	IF	Citations
55	Constraintâ€based metabolic targets for the improved production of heterologous compounds across molecular classification. AICHE Journal, 2018, 64, 4208-4217.	1.8	1
56	Editorial overview: Pharmaceutical biotechnology. Current Opinion in Biotechnology, 2021, 69, vi-viii.	3.3	1
57	Salicylate Glucoside as a Nontoxic Plant Protectant Alternative to Salicylic Acid. ACS Agricultural Science and Technology, 2021, 1, 515-521.	1.0	1
58	Yarrowia lipolytica as a Cell Factory for Oleochemical Biotechnology. , 2017, , 1-19.		1
59	A Hybrid Biologicalâ€“Biomaterial Vector for Antigen Delivery. Methods in Molecular Biology, 2021, 2183, 461-475.	0.4	1
60	Editorial overview: Pharmaceutical biotechnology: New approaches for dynamic disease targets. Current Opinion in Biotechnology, 2016, 42, vi-vii.	3.3	0
61	A Transition to Targeted or â€˜Smartâ€™ Vaccines: How Understanding Commensal Colonization Can Lead to Selective Vaccination. Pharmaceutical Medicine, 2018, 32, 95-102.	1.0	0
62	Improving E. coli by of Bacteriophage Î¦X174 Gene. Methods in Molecular Biology, 2021, 2211, 3-14.	0.4	0